Johnson & Johnson (NYSE:JNJ) Shares Purchased by Austin Private Wealth LLC

Austin Private Wealth LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 18.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,910 shares of the company’s stock after buying an additional 1,559 shares during the quarter. Austin Private Wealth LLC’s holdings in Johnson & Johnson were worth $1,433,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. IFS Advisors LLC raised its position in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after purchasing an additional 100 shares during the period. Highline Wealth Partners LLC acquired a new stake in shares of Johnson & Johnson in the third quarter valued at $31,000. RPg Family Wealth Advisory LLC acquired a new position in Johnson & Johnson during the 3rd quarter worth about $35,000. Mowery & Schoenfeld Wealth Management LLC boosted its holdings in Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after acquiring an additional 91 shares during the period. Finally, Activest Wealth Management acquired a new position in Johnson & Johnson in the 3rd quarter valued at about $40,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $151.82 on Tuesday. The company has a fifty day moving average of $147.61 and a two-hundred day moving average of $156.12. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a market capitalization of $365.53 billion, a PE ratio of 22.83, a P/E/G ratio of 2.44 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter last year, the business posted $2.29 EPS. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. As a group, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.27%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

Analysts Set New Price Targets

Several research firms have recently commented on JNJ. Leerink Partners lowered their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Guggenheim raised their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research report on Monday. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Raymond James cut their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Finally, Bank of America decreased their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.